Adam M. Petrich

2.5k total citations
57 papers, 902 citations indexed

About

Adam M. Petrich is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Adam M. Petrich has authored 57 papers receiving a total of 902 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 26 papers in Genetics and 23 papers in Oncology. Recurrent topics in Adam M. Petrich's work include Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Viral-associated cancers and disorders (15 papers). Adam M. Petrich is often cited by papers focused on Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Viral-associated cancers and disorders (15 papers). Adam M. Petrich collaborates with scholars based in United States, Japan and Netherlands. Adam M. Petrich's co-authors include Henny H. Billett, Chadi Nabhan, Sonali M. Smith, Chadi Nabhan, Steven T. Rosen, Leo I. Gordon, Mitul Gandhi, Andrew M. Evens, Shuo Ma and Jane N. Winter and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Adam M. Petrich

57 papers receiving 892 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam M. Petrich United States 17 554 388 221 190 180 57 902
ML Hansmann Germany 15 415 0.7× 348 0.9× 118 0.5× 59 0.3× 151 0.8× 31 895
Alvaro J. Alencar United States 10 369 0.7× 241 0.6× 118 0.5× 29 0.2× 217 1.2× 58 691
C Gisselbrecht France 15 543 1.0× 451 1.2× 181 0.8× 28 0.1× 152 0.8× 36 860
James T. Sundeen United States 12 554 1.0× 330 0.9× 246 1.1× 54 0.3× 62 0.3× 15 804
Jens Krugmann Austria 18 432 0.8× 402 1.0× 229 1.0× 14 0.1× 156 0.9× 41 857
Richard Delarue France 17 922 1.7× 617 1.6× 332 1.5× 27 0.1× 229 1.3× 47 1.2k
Suguru Fukuhara Japan 14 433 0.8× 260 0.7× 183 0.8× 15 0.1× 65 0.4× 83 603
Giovanna Motta Italy 15 206 0.4× 225 0.6× 86 0.4× 39 0.2× 132 0.7× 45 621
Grete F. Lauritzsen Norway 19 851 1.5× 692 1.8× 228 1.0× 25 0.1× 145 0.8× 34 1.4k
E. Januszewicz Australia 16 403 0.7× 230 0.6× 466 2.1× 25 0.1× 129 0.7× 41 957

Countries citing papers authored by Adam M. Petrich

Since Specialization
Citations

This map shows the geographic impact of Adam M. Petrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam M. Petrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam M. Petrich more than expected).

Fields of papers citing papers by Adam M. Petrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam M. Petrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam M. Petrich. The network helps show where Adam M. Petrich may publish in the future.

Co-authorship network of co-authors of Adam M. Petrich

This figure shows the co-authorship network connecting the top 25 collaborators of Adam M. Petrich. A scholar is included among the top collaborators of Adam M. Petrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam M. Petrich. Adam M. Petrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruan, Jia, Jasmine M. Zain, Borko Jovanovic, et al.. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances. 7(19). 5771–5779. 19 indexed citations
2.
Karmali, Reem, Jeremy S. Abramson, Deborah M. Stephens, et al.. (2023). Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Advances. 7(23). 7361–7368. 3 indexed citations
3.
Hong, Ying, Naoyuki Tajima, Kashyap Patel, et al.. (2023). Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development. CPT Pharmacometrics & Systems Pharmacology. 13(1). 23–28. 3 indexed citations
4.
LoRusso, Patricia, Mark J. Ratain, Toshihiko Doi, et al.. (2022). Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Investigational New Drugs. 40(4). 762–772. 19 indexed citations
5.
Major, Ajay, Justin Kline, Theodore Karrison, et al.. (2021). Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 107(7). 1608–1618. 21 indexed citations
6.
Petrich, Adam M., Leo I. Gordon, Reem Karmali, et al.. (2021). A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. Leukemia & lymphoma. 62(14). 3493–3500. 20 indexed citations
7.
Kaplan, Jason, Reem Karmali, Jane N. Winter, et al.. (2020). ABCL-283: A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) as Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 20. S271–S271. 2 indexed citations
8.
Jongen‐Lavrencic, Mojca, Junichiro Yuda, Rogier Mous, et al.. (2020). AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 20. S177–S177. 2 indexed citations
9.
Swinnen, L. J., Christopher R. Flowers, Dee Dee Wang, et al.. (2017). VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY. Hematological Oncology. 35(S2). 90–90. 4 indexed citations
10.
Galanina, Natalie, Adam M. Petrich, & Chadi Nabhan. (2016). The evolving role of lenalidomide in non-Hodgkin lymphoma. Leukemia & lymphoma. 57(7). 1507–1516. 3 indexed citations
11.
Gandhi, Mitul & Adam M. Petrich. (2014). Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma. Journal of the National Comprehensive Cancer Network. 12(1). 16–19. 9 indexed citations
12.
Evens, Andrew M., et al.. (2014). Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review. Journal of the National Comprehensive Cancer Network. 12(4). 465–471. 21 indexed citations
13.
Petrich, Adam M., Chadi Nabhan, & Sonali M. Smith. (2014). MYC‐associated and double‐hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches. Cancer. 120(24). 3884–3895. 76 indexed citations
14.
Jasielec, Jagoda, Amy Kimball, Kenneth S. Cohen, et al.. (2014). Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV).. Journal of Clinical Oncology. 32(15_suppl). 8567–8567. 2 indexed citations
15.
Gentzler, Ryan D., Andrew M. Evens, Alfred Rademaker, et al.. (2014). F‐18 FDG‐PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem‐cell transplantation for relapsed and refractory Hodgkin lymphoma. British Journal of Haematology. 165(6). 793–800. 29 indexed citations
16.
Petrich, Adam M., Violetta V. Leshchenko, Bing Xia, et al.. (2012). Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma. Clinical Cancer Research. 18(9). 2534–2544. 48 indexed citations
17.
Janakiram, Murali, et al.. (2012). Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Current Treatment Options in Oncology. 13(1). 82–101. 2 indexed citations
18.
Yang, David T., et al.. (2010). Use of Tissue Microarray and Automated Quantitative Analysis for Screening and Validation of Potential Biomarkers in Mantle Cell Lymphoma. Applied immunohistochemistry & molecular morphology. 19(1). 62–69. 6 indexed citations
19.
Petrich, Adam M., et al.. (2010). Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL. Blood. 116(21). 436–436. 4 indexed citations
20.
Petrich, Adam M., et al.. (2008). Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leukemia & lymphoma. 49(1). 57–61. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by ML Hansmann Breakdown of academic impact, for papers by Alvaro J. Alencar Breakdown of academic impact, for papers by C Gisselbrecht Breakdown of academic impact, for papers by James T. Sundeen Breakdown of academic impact, for papers by Jens Krugmann Breakdown of academic impact, for papers by Richard Delarue Breakdown of academic impact, for papers by Suguru Fukuhara Breakdown of academic impact, for papers by Giovanna Motta Breakdown of academic impact, for papers by Grete F. Lauritzsen Breakdown of academic impact, for papers by E. Januszewicz
Rankless by CCL
2026